{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:33:26Z","timestamp":1773300806408,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T00:00:00Z","timestamp":1360022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>SPARC is a matricellular glycoprotein with growth-inhibitory and antiangiogenic activity in some cell types. The study of this protein in hematopoietic malignancies led to conflicting reports about its role as a tumor suppressor or promoter, depending on its different functions in the tumor microenvironment. In this study we investigated the variations in SPARC production by peripheral blood cells from chronic myeloid leukemia (CML) patients at diagnosis and after treatment and we identified the subpopulation of cells that are the prevalent source of SPARC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We evaluated SPARC expression using real-time PCR and western blotting. SPARC serum levels were detected by ELISA assay. Finally we analyzed the interaction between exogenous SPARC and imatinib (IM), in vitro, using ATP-lite and cell cycle analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our study shows that the CML cells of patients at diagnosis have a low mRNA and protein expression of SPARC. Low serum levels of this protein are also recorded in CML patients at diagnosis. However, after IM treatment we observed an increase of SPARC mRNA, protein, and serum level in the peripheral blood of these patients that had already started at 3\u2009months and was maintained for at least the 18\u2009months of observation. This SPARC increase was predominantly due to monocyte production. In addition, exogenous SPARC protein reduced the growth of K562 cell line and synergized in vitro with IM by inhibiting cell cycle progression from G1 to S phase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results suggest that low endogenous SPARC expression is a constant feature of BCR\/ABL positive cells and that IM treatment induces SPARC overproduction by normal cells. This exogenous SPARC may inhibit CML cell proliferation and may synergize with IM activity against CML.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-60","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T13:14:05Z","timestamp":1360070045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation"],"prefix":"10.1186","volume":"13","author":[{"given":"Cesarina","family":"Giallongo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Tibullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunziatina","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cupri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe A","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,5]]},"reference":[{"issue":"5894","key":"3649_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982, 300 (5894): 765-767. 10.1038\/300765a0.","journal-title":"Nature"},{"issue":"11","key":"3649_CR2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348 (11): 994-1004. 10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"issue":"14","key":"3649_CR3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001, 344 (14): 1038-1042. 10.1056\/NEJM200104053441402.","journal-title":"N Engl J Med"},{"issue":"6","key":"3649_CR4","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002, 99 (6): 1928-1937. 10.1182\/blood.V99.6.1928.","journal-title":"Blood"},{"issue":"4","key":"3649_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-008-9146-7","volume":"27","author":"OL Podhajcer","year":"2008","unstructured":"Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27 (4): 691-705. 10.1007\/s10555-008-9146-7.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"3649_CR6","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1073\/pnas.88.7.2648","volume":"88","author":"SE Funk","year":"1991","unstructured":"Funk SE, Sage EH: The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA. 1991, 88 (7): 2648-2652. 10.1073\/pnas.88.7.2648.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3649_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0945-053X(00)00105-0","volume":"19","author":"RA Brekken","year":"2000","unstructured":"Brekken RA, Sage EH: SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 2000, 19 (7): 569-580. 10.1016\/S0945-053X(00)00105-0.","journal-title":"Matrix Biol"},{"issue":"4","key":"3649_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I","volume":"70","author":"K Motamed","year":"1998","unstructured":"Motamed K, Sage EH: SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem. 1998, 70 (4): 543-552. 10.1002\/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I.","journal-title":"J Cell Biochem"},{"issue":"45","key":"3649_CR9","doi-asserted-by":"publisher","first-page":"29635","DOI":"10.1074\/jbc.273.45.29635","volume":"273","author":"C Kupprion","year":"1998","unstructured":"Kupprion C, Motamed K, Sage EH: SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem. 1998, 273 (45): 29635-29640. 10.1074\/jbc.273.45.29635.","journal-title":"J Biol Chem"},{"issue":"4","key":"3649_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1073\/pnas.89.4.1281","volume":"89","author":"EW Raines","year":"1992","unstructured":"Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH: The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA. 1992, 89 (4): 1281-1285. 10.1073\/pnas.89.4.1281.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3649_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1476-4598-9-138","volume":"9","author":"A Chlenski","year":"2010","unstructured":"Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang Q, Tian Y, Salwen HR, Cohn SL: Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer. 2010, 9: 138-10.1186\/1476-4598-9-138.","journal-title":"Mol Cancer"},{"issue":"27","key":"3649_CR12","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1073\/pnas.0610477104","volume":"104","author":"A Pellagatti","year":"2007","unstructured":"Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, et al: Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007, 104 (27): 11406-11411. 10.1073\/pnas.0610477104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3649_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.leu.2404102","volume":"20","author":"JF DiMartino","year":"2006","unstructured":"DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006, 20 (3): 426-432. 10.1038\/sj.leu.2404102.","journal-title":"Leukemia"},{"issue":"5","key":"3649_CR14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1046\/j.1365-2141.2003.04481.x","volume":"122","author":"CV Hedvat","year":"2003","unstructured":"Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD: Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol. 2003, 122 (5): 728-744. 10.1046\/j.1365-2141.2003.04481.x.","journal-title":"Br J Haematol"},{"issue":"23","key":"3649_CR15","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","volume":"70","author":"N Fenouille","year":"2010","unstructured":"Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, et al: Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010, 70 (23): 9659-9670. 10.1158\/0008-5472.CAN-10-2034.","journal-title":"Cancer Res"},{"issue":"1","key":"3649_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2007.01.201","volume":"356","author":"K Li","year":"2007","unstructured":"Li K, Cai R, Dai BB, Zhang XQ, Wang HJ, Ge SF, Xu WR, Lu J: SATB1 regulates SPARC expression in K562 cell line through binding to a specific sequence in the third intron. Biochem Biophys Res Commun. 2007, 356 (1): 6-12. 10.1016\/j.bbrc.2007.01.201.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3649_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0002-9440(10)61732-4","volume":"159","author":"GK Yiu","year":"2001","unstructured":"Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC: SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 2001, 159 (2): 609-622. 10.1016\/S0002-9440(10)61732-4.","journal-title":"Am J Pathol"},{"issue":"2","key":"3649_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/sj.thj.6200365","volume":"5","author":"L Mazzacurati","year":"2004","unstructured":"Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS, Santucci MA: Chk2 drives late G1\/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J. 2004, 5 (2): 168-177. 10.1038\/sj.thj.6200365.","journal-title":"Hematol J"},{"issue":"8","key":"3649_CR19","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","volume":"65","author":"EJ Andreu","year":"2005","unstructured":"Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, Montiel-Duarte C, Rifon J, Perez-Calvo J, Arbona C, et al: BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005, 65 (8): 3264-3272.","journal-title":"Cancer Res"},{"issue":"1 Pt 1","key":"3649_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0092-8674(81)90037-4","volume":"26","author":"JD Termine","year":"1981","unstructured":"Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR: Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981, 26 (1 Pt 1): 99-105.","journal-title":"Cell"},{"issue":"4","key":"3649_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","volume":"37","author":"D Tibullo","year":"2009","unstructured":"Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F: Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol. 2009, 37 (4): 461-468. 10.1016\/j.exphem.2008.12.008.","journal-title":"Exp Hematol"},{"issue":"19","key":"3649_CR22","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006, 354 (19): 2006-2013. 10.1056\/NEJMoa051140.","journal-title":"N Engl J Med"},{"issue":"5","key":"3649_CR23","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","volume":"111","author":"S Fitter","year":"2008","unstructured":"Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC: Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008, 111 (5): 2538-2547. 10.1182\/blood-2007-07-104281.","journal-title":"Blood"},{"issue":"7","key":"3649_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.12373","volume":"93","author":"S Jonsson","year":"2008","unstructured":"Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H: Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008, 93 (7): 1101-1103. 10.3324\/haematol.12373.","journal-title":"Haematologica"},{"issue":"23","key":"3649_CR25","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1056\/NEJMc062388","volume":"355","author":"A Grey","year":"2006","unstructured":"Grey A, O\u2019Sullivan S, Reid IR, Browett P: Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med. 2006, 355 (23): 2494-2495. 10.1056\/NEJMc062388.","journal-title":"N Engl J Med"},{"issue":"1","key":"3649_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hon.988","volume":"30","author":"D Tibullo","year":"2012","unstructured":"Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F: Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematol Oncol. 2012, 30 (1): 27-33. 10.1002\/hon.988. Epub 2011 May 5","journal-title":"Hematol Oncol"},{"issue":"2","key":"3649_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA: JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004, 18 (2): 189-218. 10.1038\/sj.leu.2403241.","journal-title":"Leukemia"},{"issue":"5","key":"3649_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, et al: Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell. 2002, 1 (5): 479-492. 10.1016\/S1535-6108(02)00074-0.","journal-title":"Cancer Cell"},{"issue":"21","key":"3649_CR29","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/sj.onc.1203486","volume":"19","author":"TS Lin","year":"2000","unstructured":"Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000, 19 (21): 2496-2504. 10.1038\/sj.onc.1203486.","journal-title":"Oncogene"},{"issue":"4","key":"3649_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","volume":"20","author":"MS Neshat","year":"2000","unstructured":"Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL: The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000, 20 (4): 1179-1186. 10.1128\/MCB.20.4.1179-1186.2000.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"3649_CR31","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.leukres.2007.11.034","volume":"32","author":"Y Sugimoto","year":"2008","unstructured":"Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K: HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Leuk Res. 2008, 32 (6): 962-971. 10.1016\/j.leukres.2007.11.034.","journal-title":"Leuk Res"},{"issue":"2 Suppl 2","key":"3649_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/shem.2003.50035","volume":"40","author":"GQ Daley","year":"2003","unstructured":"Daley GQ: Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol. 2003, 40 (2 Suppl 2): 11-14.","journal-title":"Semin Hematol"},{"issue":"6","key":"3649_CR33","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1172\/JCI23002","volume":"115","author":"IT Tai","year":"2005","unstructured":"Tai IT, Dai M, Owen DA, Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 2005, 115 (6): 1492-1502. 10.1172\/JCI23002.","journal-title":"J Clin Invest"},{"issue":"3","key":"3649_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-06-2014","volume":"67","author":"M Holtz","year":"2007","unstructured":"Holtz M, Forman SJ, Bhatia R: Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007, 67 (3): 1113-1120. 10.1158\/0008-5472.CAN-06-2014.","journal-title":"Cancer Res"},{"issue":"4","key":"3649_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/jcb.20091","volume":"92","author":"PE Framson","year":"2004","unstructured":"Framson PE, Sage EH: SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem. 2004, 92 (4): 679-690. 10.1002\/jcb.20091.","journal-title":"J Cell Biochem"},{"issue":"8","key":"3649_CR36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.yexcr.2010.02.043","volume":"316","author":"M Jadersten","year":"2010","unstructured":"Jadersten M, Hellstrom-Lindberg E: New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp Cell Res. 2010, 316 (8): 1390-1396. 10.1016\/j.yexcr.2010.02.043.","journal-title":"Exp Cell Res"},{"issue":"11","key":"3649_CR37","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006, 107 (11): 4532-4539. 10.1182\/blood-2005-07-2947.","journal-title":"Blood"},{"issue":"1","key":"3649_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002, 99 (1): 319-325. 10.1182\/blood.V99.1.319.","journal-title":"Blood"},{"issue":"6","key":"3649_CR39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","volume":"19","author":"MS Holtz","year":"2005","unstructured":"Holtz MS, Forman SJ, Bhatia R: Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005, 19 (6): 1034-1041. 10.1038\/sj.leu.2403724.","journal-title":"Leukemia"},{"issue":"24","key":"3649_CR40","first-page":"7357","volume":"62","author":"A Chlenski","year":"2002","unstructured":"Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, et al: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62 (24): 7357-7363.","journal-title":"Cancer Res"},{"issue":"4","key":"3649_CR41","first-page":"876","volume":"96","author":"GA Palumbo","year":"1997","unstructured":"Palumbo GA, Romeo MA, Di Raimondo F, Giustolisi R: Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia. Br J Haematol. 1997, 96 (4): 876-877.","journal-title":"Br J Haematol"},{"issue":"29","key":"3649_CR42","doi-asserted-by":"publisher","first-page":"18411","DOI":"10.1074\/jbc.272.29.18411","volume":"272","author":"R Foresti","year":"1997","unstructured":"Foresti R, Clark JE, Green CJ, Motterlini R: Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem. 1997, 272 (29): 18411-18417. 10.1074\/jbc.272.29.18411.","journal-title":"J Biol Chem"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-60.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-60\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-60","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-60.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:11:36Z","timestamp":1630534296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,5]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3649"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-60","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,5]]},"assertion":[{"value":"13 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"60"}}